Jyong Biotech Ltd. (MENS)
Market Open
12 Jun, 15:05
NASDAQ (NMS) NASDAQ (NMS) Primary $
1. 68
-0.03
-1.4663%
$
130.77M Market Cap
- P/E Ratio
- Div Yield
95,456 Volume
- Eps
$ 1.71
Previous Close 
Want to track MENS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large unmet BPH, prostate cancer prevention, and IC markets. However, their botanical approach could be a potential “first‑in‑class” as a safer alternative. MENS recent IPO raised roughly $20 million and gave them a healthy cash runway. Though note that additional trials could accelerate cash burn.
Seekingalpha | 10 months ago
